AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

AstraZeneca is scheduled to report results for the third quarter on Tuesday. Here is what to know. CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

drug development and clinical oncology, is pleased to announce the publication of research investigating the dual analysis of CTCs and circulating tumour DNA (ctDNA) in non-small cell lung cancer ...

The Guildford, England-based liquid biopsy company said the study undertaken by the National & Kapodistrian University of Athens used the Parsortix system to isolate and harvest circulating tumour ...

AstraZeneca (AZ) has begun the second quarter on the front foot with a filing for a potential first-in-class cancer drug in the US, and an application to expand the use of its ovarian cancer drug ...

to develop and commercialize a subcutaneous version of ENHERTU ® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC) that has been jointly developed and commercialized by ...

The US Food and Drug Administration (FDA) has announced it has approved colon cancer drug, Zaltrap, for use in combination with a folinic acid, fluorouracil and iriontecan (FOLFIRI) chemotherapy ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s ...

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a ...